S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

CareDx Stock Forecast, Price & News

-0.35 (-1.46%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.61 million shs
Average Volume
835,288 shs
Market Capitalization
$1.26 billion
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive CDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter.

CDNA Stock Forecast (MarketRank)

Overall MarketRank

1.92 out of 5 stars

Medical Sector

665th out of 1,417 stocks

Medical Laboratories Industry

17th out of 31 stocks

Analyst Opinion: 3.6Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
CareDx logo

About CareDx (NASDAQ:CDNA)

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Stock News Headlines

CareDx Deadline Alert
CareDx Deadline Alert - Benzinga - Benzinga
CareDx, Inc (NASDAQ:CDNA) Short Interest Down 25.8% in May
CareDx (NASDAQ:CDNA) Trading Down 4.2%
See More Headlines

Industry, Sector and Symbol

Medical laboratories
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
$-30.66 million
Pretax Margin


Sales & Book Value

Annual Sales
$296.40 million
Book Value
$8.82 per share


Free Float
Market Cap
$1.26 billion

CareDx Frequently Asked Questions

Should I buy or sell CareDx stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CareDx in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CareDx stock.
View analyst ratings for CareDx
or view top-rated stocks.

What is CareDx's stock price forecast for 2022?

4 analysts have issued 1 year target prices for CareDx's stock. Their CDNA stock forecasts range from $50.00 to $110.00. On average, they predict CareDx's stock price to reach $72.80 in the next twelve months. This suggests a possible upside of 207.4% from the stock's current price.
View analysts' price targets for CareDx
or view top-rated stocks among Wall Street analysts.

How has CareDx's stock performed in 2022?

CareDx's stock was trading at $45.48 at the beginning of 2022. Since then, CDNA stock has decreased by 47.9% and is now trading at $23.68.
View the best growth stocks for 2022 here

Are investors shorting CareDx?

CareDx saw a drop in short interest in May. As of May 31st, there was short interest totaling 3,160,000 shares, a drop of 25.8% from the May 15th total of 4,260,000 shares. Based on an average trading volume of 868,300 shares, the days-to-cover ratio is currently 3.6 days.
View CareDx's Short Interest

When is CareDx's next earnings date?

CareDx is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for CareDx

How were CareDx's earnings last quarter?

CareDx, Inc (NASDAQ:CDNA) announced its quarterly earnings results on Thursday, May, 5th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.07. The firm earned $79.42 million during the quarter, compared to the consensus estimate of $78.63 million. CareDx had a negative net margin of 16.09% and a negative trailing twelve-month return on equity of 10.58%.
View CareDx's earnings history

What guidance has CareDx issued on next quarter's earnings?

CareDx updated its FY 2022 earnings guidance on Monday, May, 23rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $330.00 million-$350.00 million, compared to the consensus revenue estimate of $342.22 million.

Who are CareDx's key executives?

CareDx's management team includes the following people:
  • Dr. Reginald Seeto, Pres, CEO & Director (Age 50, Pay $1.51M) (LinkedIn Profile)
  • Ms. Sasha King M.B.A., Chief Marketing Officer & Franchise Head of Kidney Transplant (Age 36, Pay $628.87k) (LinkedIn Profile)
  • Dr. Peter Maag Ph.D., Exec. Director (Age 55, Pay $791.45k)
  • Mr. Marcel Konrad, Sr. VP of Fin. & Accounting (Age 46, Pay $167.96k)
  • Mr. Alexander L. Johnson, Chief Bus. Officer & Head of Testing Services (Age 47, Pay $716.54k)
  • Mr. Ankur Dhingra, Consultant (Age 46, Pay $909.26k) (LinkedIn Profile)
  • Mr. Abhishek Jain, Interim CFO, VP, Corp. Controller, Principal Financial Officer & Principal Accounting Officer (Age 46)
  • Mr. Ian Cooney, VP of Investor Relations
  • Mr. Abraham Ronai Esq., Gen. Counsel
  • Dr. Mickey Y. Kim M.D., Sr. VP of Corp. Devel. & Strategy

What other stocks do shareholders of CareDx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CareDx investors own include Square (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Enphase Energy (ENPH), Johnson & Johnson (JNJ), Activision Blizzard (ATVI) and Alibaba Group (BABA).

What is CareDx's stock symbol?

CareDx trades on the NASDAQ under the ticker symbol "CDNA."

Who are CareDx's major shareholders?

CareDx's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.73%), BlackRock Inc. (7.27%), ARK Investment Management LLC (6.62%), State Street Corp (5.71%), Bellevue Group AG (4.34%) and Invesco Ltd. (4.20%). Company insiders that own CareDx stock include Ankur Dhingra, George Bickerstaff, Grace Colon, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas and William A Hagstrom.
View institutional ownership trends for CareDx

Which major investors are selling CareDx stock?

CDNA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Invesco Ltd., ARK Investment Management LLC, Citigroup Inc., Goldman Sachs Group Inc., Granite Investment Partners LLC, BlackRock Inc., and Canada Pension Plan Investment Board. Company insiders that have sold CareDx company stock in the last two years include George Bickerstaff, Grace Colon, Michael Brian Bell, Michael Goldberg, Paul Adler, Peter Maag, Ralph Snyderman, Reginald Seeto, Sasha King, Thomas A Thomas, and William A Hagstrom.
View insider buying and selling activity for CareDx
or view top insider-selling stocks.

Which major investors are buying CareDx stock?

CDNA stock was purchased by a variety of institutional investors in the last quarter, including Bellevue Group AG, State Street Corp, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., Renaissance Technologies LLC, Next Century Growth Investors LLC, Blue Water Life Science Advisors LP, and Bank of America Corp DE.
View insider buying and selling activity for CareDx
or or view top insider-buying stocks.

How do I buy shares of CareDx?

Shares of CDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CareDx's stock price today?

One share of CDNA stock can currently be purchased for approximately $23.68.

How much money does CareDx make?

CareDx (NASDAQ:CDNA) has a market capitalization of $1.26 billion and generates $296.40 million in revenue each year. The company earns $-30.66 million in net income (profit) each year or ($0.950010) on an earnings per share basis.

How many employees does CareDx have?

CareDx employs 633 workers across the globe.

How can I contact CareDx?

CareDx's mailing address is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. The official website for CareDx is www.caredxinc.com. The company can be reached via phone at (415) 287-2300, via email at [email protected], or via fax at 415-287-2450.

This page (NASDAQ:CDNA) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.